Chronic Kidney Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Chronic Kidney Disease Treatment Market is projected to expand from USD 37.07 Billion in 2025 to USD 48.86 Billion by 2031, registering a CAGR of 4.71%. This sector covers various therapeutic measures designed to handle declining renal function, ranging from pharmacological treatments and dialysis to kidney transplantation. Growth is largely fueled by the rising global prevalence of lifestyle-related conditions such as hypertension and diabetes, in addition to an aging population more prone to renal failure. Highlighting the urgent need for medical solutions, the International Society of Nephrology estimated in 2024 that over 850 million people worldwide were suffering from some form of kidney disease.

Conversely, the market encounters significant hurdles due to the exorbitant costs linked to advanced replacement therapies and long-term renal care. In numerous developing areas, the absence of adequate healthcare infrastructure and comprehensive reimbursement systems denies a substantial portion of the populace access to essential treatments. These economic disparities and financial obstacles represent a major challenge that threatens to severely limit the wider growth and reach of the global treatment industry.

Market Drivers

The rising prevalence of diabetes-related nephropathy acts as a major catalyst for the Global Chronic Kidney Disease Treatment Market. Elevated blood sugar levels in diabetics gradually impair the renal filtration mechanism, resulting in diabetic kidney disease, which constitutes a significant share of end-stage renal disease cases worldwide. This connection guarantees a steady and increasing stream of patients needing therapeutic intervention and chronic management. As noted in the 'IDF Diabetes Atlas 11th Edition' released by the International Diabetes Federation in April 2025, 11.1% of the global adult population is living with diabetes, forming a vast pool of individuals at high risk for renal complications.

Simultaneously, the market is being transformed by breakthroughs in novel pharmacological therapies and biologics that aim to slow disease progression rather than simply address symptoms. The widespread adoption of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors has generated significant revenue and enhanced patient care. For example, Boehringer Ingelheim reported in their April 2025 R&D investment update that sales of Jardiance, a drug for chronic kidney disease, increased by 14.6% to EUR 8.4 billion. This uptake in pharmaceuticals is crucial given the limited availability of cures; the American Kidney Fund noted that only 28,492 patients in the United States received a transplant in 2024, highlighting the heavy dependence on dialysis and medication.

Market Challenges

The exorbitant expenses tied to advanced replacement therapies and long-term renal care create a significant obstacle to the expansion of the Global Chronic Kidney Disease Treatment Market. Despite the increasing incidence of renal insufficiency, the high cost of procedures such as transplantation and dialysis precludes a large segment of patients from receiving essential care. This problem is especially severe in developing regions lacking sufficient healthcare infrastructure and robust reimbursement frameworks. Consequently, the market fails to realize the full economic potential of the expanding patient base, as financial limitations restrict the uptake of therapeutic solutions.

Data from the International Society of Nephrology in 2024 indicates that full public funding for hemodialysis was accessible in merely 28% of participating low and lower-middle-income nations. This figure underscores the profound economic inequality that limits market reach in these areas. In the absence of sufficient funding structures, the critical clinical requirement for kidney disease management cannot evolve into viable commercial demand, thereby hindering broader industry growth and restricting revenue generation largely to developed countries with established healthcare support.

Market Trends

The movement toward home-based dialysis using wearable and portable technologies is transforming the market by mitigating the financial and logistical challenges of conventional in-center care. This trend involves the creation of connected, easy-to-use dialysis systems that enable patients to handle end-stage renal disease from home, enhancing their quality of life while minimizing the risk of hospital-acquired infections. Supported by clinical advocacy for remote care and favorable reimbursement rules, this shift relieves pressure on strained healthcare facilities. As evidence of this growing adoption, DaVita’s '2024 Community Care' report from May 2025 noted that over 15% of their patients performed dialysis at home, indicating a structural shift toward decentralized treatment.

Concurrently, the incorporation of artificial intelligence for risk stratification and early disease detection is setting a new standard in precision renal care, shifting the focus from reactive treatment to predictive intervention. By utilizing novel biomarkers and sophisticated machine learning algorithms, medical professionals can detect patients prone to rapid kidney function decline much earlier than before, allowing for timely treatments that delay the need for dialysis. This technological progress is validated by rising commercial adoption and payer coverage; for instance, Renalytix reported in their March 2025 'Half-year Report' that revenue from commercial insurance reimbursed testing rose by 28%, highlighting the growing clinical and market value of AI-powered diagnostics.

Key Players Profiled in the Chronic Kidney Disease Treatment Market

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories:

Chronic Kidney Disease Treatment Market, by Product Type:

• Diagnosis
• Treatment
• Dialysis
• Others

Chronic Kidney Disease Treatment Market, by End User:

• Hospital
• Diagnostic Laboratories
• Other

Chronic Kidney Disease Treatment Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.